This Is Not The Medical Marijuana Stock That You Want

I like the risk-reward situation here, at a market cap under $700 million, than I did when the company was over $1.2 billion, but only for an investor that’s willing to hold for multiple years. In this biotech market, it’s hard to say whether GW Pharmaceuticals has hit bottom, especially since it’s trading considerably... more →
Posted in: Investing, News